Biotechnology & Medical Research

Page 1

Progen Pharmaceuticals Limited announces successfully completes third patient Cohort

8:00pm EST

Progen Pharmaceuticals Limited:Says that it has completed assessment of the third patient cohort in its PG545 Phase 1 clinical trial.Progen together with an independent medical monitor and the co-ordinating investigators have reviewed the safety data from this cohort and have agreed to progress to the next dose level of PG545.Each patient in the third cohort received once-weekly 100mg doses of PG545.Says no dose limiting toxicities were reported from the group following at least four weeks of treatment.Says accordingly, the recruitment of the fourth cohort of three patients has commenced.Each of the patients in the fourth group will receive 150mg doses of PG545 at once-weekly intervals.

Juno Therapeutics, Inc announces pricing of Initial Public Offering

6:14pm EST

Juno Therapeutics, Inc:Announces pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share.Says in addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any.Juno Therapeutics' common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol "JUNO" on Dec. 19, 2014.The offering is expected to close on Dec. 23, 2014.Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. are acting as lead book-running managers for the offering.Leerink Partners LLC is acting as a co-manager.

Aldeyra Therapeutics submits FDA IND filing for Noninfectious Anterior Uveitis

8:30am EST

Aldeyra Therapeutics Inc:Announces that an Investigational New Drug application (IND) to conduct Phase 2 clinical testing of NS2.Says for treatment of noninfectious anterior uveitis, was submitted to United States Food and Drug Administration (FDA) on Dec. 16.

Bellicum Pharmaceuticals Inc prices initial public offering of 7,350,000 shares of common stock

7:00am EST

Bellicum Pharmaceuticals Inc:Announced the pricing of its initial public offering of 7,350,000 shares of its common stock, an increase of 1,100,000 shares from the number of shares originally offered, at a public offering price of $19.00 per share.Says all of the shares of common stock are being offered by Bellicum.Says its common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading on Dec. 18 under the ticker symbol BLCM.Jefferies LLC, Citigroup Global Markets Inc. and Piper Jaffray & Co. are acting as joint book running managers for the offering.Trout Capital LLC is acting as co-manager for the offering.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.